Will Trump’s 200% Tariffs Hurt India’s Pharma Exports? Here’s What We Know

Washington: US President Donald Trump has announced that imported generic medicines will remain exempt from tariffs for the next two years but warned they could face duties of up to 100 per cent initially and 200 per cent later if manufacturers fail to shift production to the United States.

This move is part of his drive as he wants enhancement of domestic manufacturing and reduce support on imported pharmaceuticals. The proposal could significantly impact India, one of the world’s largest suppliers of generic medicines and a major exporter to the US.

However, the tariff plan has not yet completed the formal policy and rule-making process, and its details may still change.